Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoetermeer Study
NL-OMON28735Active, not recruiting
- Sponsor
- Schering AG
- Start
- Jan 1996
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of atamestane and dehydroepiandrosterone in Fragility, sponsored by Schering AG. Primary endpoints: Isometric Grip Strength and Physical Performance (according to Guralnik). Started Jan 1996; status: active, not recruiting.
02
Drugs
atamestanedehydroepiandrosterone
03
Conditions
Fragility
Beyond the preview
Go deeper on NL-OMON28735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28735.